Yufeng Zhou

Prof. Dr. Yufeng Zhou

Fudan University, Shanghai, China
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2021 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
LYLan Yang
Lan Yang
XXXueru Xie
Xueru Xie
ZTZikun Tu
Zikun Tu
JFJinrong Fu
Jinrong Fu
DXDamo Xu
Damo Xu
YZYufeng Zhou
Yufeng Zhou
The Coronavirus Disease 2019 (COVID-19) pandemic has become a global crisis and is more devastating than any other previous infectious disease. It has affected a significant proportion of the global population both physically and mentally, and destroyed businesses and societies. Current evidence suggested that immunopathology may be responsible for COVID-19 pathogenesis, including lymphopenia, neutrophilia, dysregulation of monocytes and macrophages, reduced or delayed type I interferon (IFN-I) response, antibody-dependent enhancement, and especially, cytokine storm (CS). The CS is characterized by hyperproduction of an array of pro-inflammatory cytokines and is closely associated with poor prognosis. These excessively secreted pro-inflammatory cytokines initiate different inflammatory signaling pathways via their receptors on immune and tissue cells, resulting in complicated medical symptoms including fever, capillary leak syndrome, disseminated intravascular coagulation, acute respiratory distress syndrome, and multiorgan failure, ultimately leading to death in the most severe cases. Therefore, it is clinically important to understand the initiation and signaling pathways of CS to develop more effective treatment strategies for COVID-19. Herein, we discuss the latest developments in the immunopathological characteristics of COVID-19 and focus on CS including the current research status of the different cytokines involved. We also discuss the induction, function, downstream signaling, and existing and potential interventions for targeting these cytokines or related signal pathways. We believe that a comprehensive understanding of CS in COVID-19 will help to develop better strategies to effectively control immunopathology in this disease and other infectious and inflammatory diseases.

1 June 2019 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
JYJinlei Yu
Jinlei Yu
YLYang Luo
Yang Luo
ZZZhenlai Zhu
Zhenlai Zhu
YZYufeng Zhou
Yufeng Zhou
LSLicheng Sun
Licheng Sun
WLWei Li
Wei Li

27 August 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LYLan Yang
Lan Yang
JFJinrong Fu
Jinrong Fu
YZYufeng Zhou
Yufeng Zhou
The incidence of allergic diseases continues to rise. Cross-sectional and longitudinal studies have indicated that allergic diseases occur in a time-based order: from atopic dermatitis and food allergy in infancy to gradual development into allergic asthma and allergic rhinitis in childhood. This phenomenon is defined as the “atopic march”. Some scholars have suggested that the atopic march does not progress completely in a temporal pattern with genetic and environmental factors. Also, the mechanisms underlying the atopic march are incompletely understood. Nevertheless, the concept of the atopic march provides a new perspective for the mechanistic research, prediction, prevention, and treatment of atopic diseases. Here, we review the epidemiology, related diseases, mechanistic studies, and treatment strategies for the atopic march.

26 April 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
CZCaiyan Zhang
Caiyan Zhang
JFJinrong Fu
Jinrong Fu
YZYufeng Zhou
Yufeng Zhou
Over 100 types of cellular RNA modifications have been identified in both coding and a variety of non-coding RNAs. N6-methyladenosine (m6A) is the most prevalent and abundant post-transcriptional RNA modification on eukaryote mRNA, and its biological functions are mediated by special binding proteins (i.e., methyltransferases, demethylases, and effectors) that recognize this modification. The presence of m6A on transcripts contributes to diverse fundamental cellular functions, such as pre-mRNA splicing, nuclear transport, stability, translation, and microRNA biogenesis, implying an association with numerous human diseases. This review principally summarizes recent progress in the study of m6A methylation mechanisms and relevant roles they play in immunoregulation.

7 March 2022 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
LCLei-Lei Chen
Lei-Lei Chen
CMCarmen Morcelle
Carmen Morcelle
ZCZhou-Li Cheng
Zhou-Li Cheng
XCXiufei Chen
Xiufei Chen
YXYanping Xu
Yanping Xu
DYDan Ye
Dan Ye

26 October 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
XYXiaoxiao Yuan
Xiaoxiao Yuan
RWRuirui Wang
Ruirui Wang
BHBing Han
Bing Han
CSChengjun Sun
Chengjun Sun
RCRuimin Chen
Ruimin Chen
FLFeihong Luo
Feihong Luo
Gut dysbiosis has been linked to type 1 diabetes (T1D); however, microbial capacity in T1D remains unclear. Here, we integratively profiled gut microbial functional and metabolic alterations in children with new-onset T1D in independent cohorts and investigated the underlying mechanisms. In T1D, the microbiota was characterized by decreased butyrate production and bile acid metabolism and increased lipopolysaccharide biosynthesis at the species, gene, and metabolite levels. The combination of 18 bacterial species and fecal metabolites provided excellently discriminatory power for T1D. Gut microbiota from children with T1D induced elevated fasting glucose levels and declined insulin sensitivity in antibiotic-treated mice. In streptozotocin-induced T1D mice, butyrate and lipopolysaccharide exerted protective and destructive effects on islet structure and function, respectively. Lipopolysaccharide aggravated the pancreatic inflammatory response, while butyrate activated Insulin1 and Insulin2 gene expression. Our study revealed perturbed microbial functional and metabolic traits in T1D, providing potential avenues for microbiome-based prevention and intervention for T1D.